Cipaglucosidase alfa-atga Inhibitors
1 drugsAbout Cipaglucosidase alfa-atga
Cipaglucosidase alfa is the target of the FDA-approved drug OPFOLDA. Its function and mechanism are crucial for understanding its therapeutic role.
Currently, there is no genetic evidence directly linking Cipaglucosidase alfa to specific diseases. However, the existence of OPFOLDA suggests a significant role in a disease process.
Cipaglucosidase alfa is targeted by one approved drug, OPFOLDA, which is a small molecule. AMICUS THERAP US is the sole company with an approved drug targeting this protein.
Top Cipaglucosidase alfa-atga Drugs
AMICUS THERAP US is the only company with an approved drug for this target.
The lack of competition represents a high-risk, high-reward opportunity.
Cipaglucosidase alfa-atga Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Cipaglucosidase alfa-atga, using small molecule modality.
Exploring alternative modalities could provide a competitive advantage.
Cipaglucosidase alfa-atga Clinical Trials 13 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Cipaglucosidase alfa-atga. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 | 100% |
| Phase 2 | 4 | 4 | 0 | 0 | 100% |
| Phase 3 | 6 | 2 | 1 | 3 | 67% |
| Phase 4 | 2 | 1 | 1 | 0 | 50% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved Cipaglucosidase alfa-atga drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting Cipaglucosidase alfa-atga. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Cipaglucosidase alfa-atga Drug Approval Timeline (2023 - 2023)
The first and only drug, OPFOLDA, was approved in 2023.
Recent approval suggests growing interest, but market saturation is low.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 9 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Cipaglucosidase alfa-atga. A trial counts if an approved drug acting on Cipaglucosidase alfa-atga is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.